# FDA 483 - American Regent, Inc. - January 25, 2019

Source: https://www.keypedia.com/records/483/american-regent-inc/53bc2bb3-5c5f-464c-8d61-1a04e622d4f7

> FDA 483 for American Regent, Inc. on January 25, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: American Regent, Inc.
- Inspection Date: 2019-01-25
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: HBT Labs, Inc. in Brea, CA, underwent an FDA inspection from January 7-25, 2019, regarding its manufacturing of Paclitaxel Albumin Bound Bulk Suspension. The inspection revealed significant deficiencies across multiple areas, including inadequate method validation, data integrity issues, incomplete batch and master production records, lack of written procedures for critical processes, and failures in quality control unit responsibilities and supplier qualification. These findings indicate a broad lack of adherence to cGMP requirements, posing potential risks to drug product quality and purity.

## Related Documents

- [483 - 2024-07-19](https://www.keypedia.com/records/483/american-regent-inc/d76ba2a2-c5ad-43ea-aea5-0faebbb9b302)

## Related Officers

- [Haitao Li](https://www.keypedia.com/people/haitao-li/62ce7565-d80f-4570-962a-8e6bfc88d0c1)
- [Team Biologics Staff](https://www.keypedia.com/people/linda-thai/f4d9a1c3-e5e8-4f13-8abe-e1f1e597c8f8)

Company: https://www.keypedia.com/companies/american-regent-inc/21f33c7b-787d-42ab-8a09-dd32403daba2

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6